JP7478142B2 - Ｓａｒｍ１阻害剤 - Google Patents

Ｓａｒｍ１阻害剤 Download PDF

Info

Publication number
JP7478142B2
JP7478142B2 JP2021518046A JP2021518046A JP7478142B2 JP 7478142 B2 JP7478142 B2 JP 7478142B2 JP 2021518046 A JP2021518046 A JP 2021518046A JP 2021518046 A JP2021518046 A JP 2021518046A JP 7478142 B2 JP7478142 B2 JP 7478142B2
Authority
JP
Japan
Prior art keywords
certain embodiments
disease
sarm1
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528488A (ja
JP2021528488A5 (enExample
Inventor
ロバート・オーエン・ヒューズ
ラジェシュ・デブラジ
トッド・ボサナック
リチャード・アンドリュー・ジャージェス－パイク
アンドリュー・サイモン・ブリアリー
ジョナサン・ベントリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disarm Therapeutics Inc
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of JP2021528488A publication Critical patent/JP2021528488A/ja
Publication of JP2021528488A5 publication Critical patent/JP2021528488A5/ja
Application granted granted Critical
Publication of JP7478142B2 publication Critical patent/JP7478142B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2021518046A 2018-06-07 2019-06-06 Ｓａｒｍ１阻害剤 Active JP7478142B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682045P 2018-06-07 2018-06-07
US62/682,045 2018-06-07
PCT/US2019/035839 WO2019236884A1 (en) 2018-06-07 2019-06-06 Inhibitors of sarm1

Publications (3)

Publication Number Publication Date
JP2021528488A JP2021528488A (ja) 2021-10-21
JP2021528488A5 JP2021528488A5 (enExample) 2022-06-10
JP7478142B2 true JP7478142B2 (ja) 2024-05-02

Family

ID=68770684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518046A Active JP7478142B2 (ja) 2018-06-07 2019-06-06 Ｓａｒｍ１阻害剤

Country Status (7)

Country Link
US (1) US12448374B2 (enExample)
EP (1) EP3801499B1 (enExample)
JP (1) JP7478142B2 (enExample)
CN (1) CN112839648B (enExample)
ES (1) ES2988933T3 (enExample)
MA (1) MA52809A (enExample)
WO (1) WO2019236884A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839647B (zh) 2018-06-07 2025-09-23 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
US12595252B2 (en) 2019-06-14 2026-04-07 Disarm Therapeutics, Inc. Inhibitors of SARM1
CA3150878A1 (en) 2019-09-12 2021-03-18 Jonathan Bentley Inhibitors of sarm1
JP7528212B2 (ja) * 2019-11-26 2024-08-05 ディスアーム セラピューティクス， インコーポレイテッド 神経保護のための方法および組成物
US12435084B2 (en) 2020-04-09 2025-10-07 Eli Lilly And Company Indazole derivatives as inhibitors of SARM1
US12606558B2 (en) 2020-04-09 2026-04-21 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of SARM1
TWI904906B (zh) 2020-08-24 2025-11-11 美商達薩瑪治療公司 Sarm1之抑制劑
EP4615448A1 (en) * 2022-11-12 2025-09-17 Cambridge Enterprise Limited Sarm1 agents for use in therapy and cosmetics
TW202509019A (zh) * 2023-04-27 2025-03-01 香港商維泰瑞隆（香港）生物科技有限公司 Sarm1調節子、其製劑及用途
CN116836162B (zh) * 2023-05-24 2025-09-05 南方医科大学 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153828A1 (en) 2005-04-05 2008-06-26 Elizabeth Aaron Collins Imidazopyridazine Compounds
WO2009041567A1 (ja) 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体
JP2011530500A (ja) 2008-08-06 2011-12-22 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
JP2013519681A (ja) 2010-02-11 2013-05-30 オーエスアイ・ファーマシューティカルズ，エルエルシー ７−アミノフロピリジン誘導体
JP2014509313A (ja) 2011-02-01 2014-04-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ７−アザインドール誘導体
WO2014198848A2 (en) 2013-06-12 2014-12-18 Lytix Biopharma As Compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018071794A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148289B (en) * 1983-10-17 1987-09-23 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
WO2000026211A1 (en) * 1998-10-30 2000-05-11 Merck & Co., Inc. Thrombin inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
US7109208B2 (en) * 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
CA2462453C (en) 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004039815A2 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
AP2005003336A0 (en) 2002-12-11 2005-06-30 Pharmacia & Upjohn Co Llc Combination for the treatment of ADHD
PL377777A1 (pl) 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
EP1587511A2 (en) 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Treatment of diseases with alpha-7 nach receptor full agonists
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
CA2572047C (en) 2004-07-21 2014-04-08 Applied Research Systems Ars Holding N.V. Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof
KR100958829B1 (ko) 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
WO2006061212A1 (en) 2004-12-08 2006-06-15 Johannes Gutenberg-Universität Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
PT1906965E (pt) 2005-06-22 2015-09-03 Chemocentryx Inc Compostos de azaindazol e métodos de utilização
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
CN101003537A (zh) 2006-01-17 2007-07-25 上海恒瑞医药有限公司 吡咯并哒嗪类衍生物及其制备方法和用途
GB0705803D0 (en) 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
AU2008241488A1 (en) 2007-04-16 2008-10-30 Merck Sharp & Dohme Corp. Bicyclic anilide heterocyclic CGRP receptor antagonists
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
MY153715A (en) 2008-11-14 2015-03-13 Merial Ltd Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
JP2011178779A (ja) 2010-02-04 2011-09-15 Daiichi Sankyo Co Ltd イミダゾピリジン−２−オン誘導体
WO2011096490A1 (ja) 2010-02-04 2011-08-11 第一三共株式会社 イミダゾピリジン－２－オン誘導体
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
PT2661433T (pt) 2011-01-04 2017-10-24 Novartis Ag Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
PH12013502020A1 (en) 2011-04-05 2018-04-11 Pfizer Ltd Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
AR092289A1 (es) 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN102532027A (zh) 2012-03-01 2012-07-04 常州协丰医药研发有限公司 一种通过羟胺活化来形成吲唑衍生物的合成方法
CN102675310B (zh) 2012-05-09 2014-12-24 林辉 制备吡唑并芳杂环化合物的方法
EP2855477A4 (en) 2012-05-29 2015-11-18 Merck Sharp & Dohme ISOTOPICALLY MARKED BIARYL UREA COMPOUNDS
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
CA2882724A1 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
BR112015022643A2 (pt) 2013-03-12 2017-07-18 Abbvie Inc inibidores diidro-pirrolpiridinona
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
EA027936B1 (ru) 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9732103B2 (en) * 2014-02-25 2017-08-15 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
ES2774923T3 (es) 2014-04-28 2020-07-23 China Resources Pharmaceutical Holdings Company Ltd Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa
WO2015191403A1 (en) 2014-06-13 2015-12-17 Bristol-Myers Squibb Company Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
ES2708965T3 (es) 2014-06-13 2019-04-12 Bristol Myers Squibb Co Compuestos tricíclicos como ligandos del receptor de alfa-7 nicotínico de acetilcolina
CN111253424B (zh) 2014-08-06 2023-06-20 加州理工学院 芳族杂环通过地球丰富的无过渡金属的催化剂的甲硅烷基化
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
KR102523405B1 (ko) 2014-10-23 2023-04-18 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸로피리미딘 유도체
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016100157A2 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
CA2979302A1 (en) 2015-05-13 2016-11-17 Selvita S.A. Substituted quinoxaline derivatives
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
ES2821896T3 (es) 2015-08-05 2021-04-28 Indivior Uk Ltd Antagonistas del receptor de dopamina D3 que tienen una unidad estructural biciclo
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2017202748A1 (en) 2016-05-24 2017-11-30 Merck Patent Gmbh Tricyclic heterocylic derivatives
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018035204A1 (en) 2016-08-16 2018-02-22 Henry Ford Health System Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
JP7044789B2 (ja) 2016-09-24 2022-03-30 ワシントン・ユニバーシティ Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用
MX385576B (es) 2016-11-02 2025-03-18 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
WO2018149986A1 (en) 2017-02-16 2018-08-23 Oryzon Genomics, S.A. 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018210229A1 (zh) 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 α-7尼古丁乙酰胆碱受体激动剂及应用
WO2019034890A1 (en) 2017-08-18 2019-02-21 Cancer Research Technology Limited PYRROLO [2,3-B] PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2019106087A1 (en) 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
CA3118400A1 (en) 2017-12-01 2019-06-06 The Board Of Trustees Of The University Of Illinois Pyridinone-based epigenetic modifiers and uses thereof
SG11202005254RA (en) 2017-12-05 2020-07-29 Oryzon Genomics Sa 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
MX2020008265A (es) 2018-02-16 2020-09-21 UCB Biopharma SRL Derivados farmaceuticos del anillo heterobiciclico 6,5.
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
JP2019182784A (ja) 2018-04-10 2019-10-24 大日本住友製薬株式会社 ジヒドロピラゾロピラジノン誘導体
EP3774775B8 (en) 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
US11882759B2 (en) 2018-04-13 2024-01-23 Universal Display Corporation Organic electroluminescent materials and devices
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
CN112839647B (zh) 2018-06-07 2025-09-23 达萨玛治疗公司 Sarm1抑制剂
CA3108669A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
AU2019319907B2 (en) 2018-08-09 2024-09-05 Valo Health, Inc. Carboxamides as ubiquitin-specific protease inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153828A1 (en) 2005-04-05 2008-06-26 Elizabeth Aaron Collins Imidazopyridazine Compounds
WO2009041567A1 (ja) 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体
JP2011530500A (ja) 2008-08-06 2011-12-22 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
JP2013519681A (ja) 2010-02-11 2013-05-30 オーエスアイ・ファーマシューティカルズ，エルエルシー ７−アミノフロピリジン誘導体
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
JP2014509313A (ja) 2011-02-01 2014-04-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ７−アザインドール誘導体
WO2014198848A2 (en) 2013-06-12 2014-12-18 Lytix Biopharma As Compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018071794A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fisher, M. H. et al.，Azaindole anthelmintic agents，Journal of Medicinal Chemistry，1972年，Vol.15, No.11，pp.1168-1171
Gallou, Fet al.，Practical regioselective bromination of azaindoles and diazaindoles，Synlett，2007年，No.2，pp.211-214
REGISTRY[online]，2009.10.27-2012.7.23, [Retrieved on 2023.5.19], Retrieved from：STN, CAS登録番号 1190318-02-5、1384079-12-2

Also Published As

Publication number Publication date
JP2021528488A (ja) 2021-10-21
US20220194933A1 (en) 2022-06-23
CN112839648B (zh) 2025-04-04
ES2988933T3 (es) 2024-11-22
WO2019236884A1 (en) 2019-12-12
MA52809A (fr) 2021-04-14
CN112839648A (zh) 2021-05-25
EP3801499A4 (en) 2022-01-12
EP3801499A1 (en) 2021-04-14
US12448374B2 (en) 2025-10-21
EP3801499B1 (en) 2024-02-28
CA3102598A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP7478142B2 (ja) Ｓａｒｍ１阻害剤
JP7576145B2 (ja) Ｓａｒｍ１阻害剤
JP7659110B2 (ja) Ｓａｒｍ１の阻害剤
CN113966217B (zh) Sarm1抑制剂
JP7289375B2 (ja) Ｓａｒｍ１の阻害剤
JP7478252B2 (ja) Ｓａｒｍ１の阻害剤
JP7534390B2 (ja) Ｓａｒｍ１の阻害剤
JP7477642B2 (ja) Ｓａｒｍ１の阻害剤
JP7746384B2 (ja) Ｓａｒｍ１のベンゾピラゾール阻害剤
CA3102598C (en) Inhibitors of sarm1

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240419

R150 Certificate of patent or registration of utility model

Ref document number: 7478142

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150